Biomarker-Guided Targeted Nanomedicine

Abstract

Nanomedicine has emerged as a powerful approach for improving the diagnosis and treatment of complex diseases by utilizing nanoscale drug delivery systems. Conventional therapeutic methods often suffer from limitations such as poor solubility, non-specific distribution, rapid systemic clearance, and associated toxicity. Nanocarrier-based systems address these challenges by enhancing drug stability, improving pharmacokinetic behavior, and enabling controlled and site-specific delivery of therapeutic agents. In recent years, the integration of biomarkers with nanotechnology has significantly advanced targeted therapeutic strategies and contributed to the evolution of precision medicine (2,3,4). Biomarkers, including proteins, genes, enzymes, and metabolites, serve as measurable indicators of physiological and pathological conditions and play a crucial role in disease diagnosis, prognosis, and therapeutic response (11,12,13). Biomarker-guided targeted nanomedicine involves engineering nanoparticles capable of selectively recognizing and interacting with biomarker-expressing cells or tissues. Functionalization of nanocarriers with ligands such as antibodies, peptides, or small molecules allows precise drug delivery to diseased sites, thereby enhancing therapeutic efficacy while minimizing off-target effects. This approach has demonstrated considerable potential, particularly in cancer therapy, where biomarkers such as HER2, EGFR, and VEGF are widely utilized for targeted drug delivery(59,60,61). Furthermore, emerging applications in cardiovascular, neurological, and infectious diseases highlight the broader clinical relevance of this strategy. However, challenges such as biomarker heterogeneity, nanoparticle safety, large-scale manufacturing, and regulatory issues remain to be addressed. Continued interdisciplinary research is essential to optimize biomarker identification, nanocarrier design, and clinical translation, ultimately enabling more effective and personalized therapeutic interventions (38,39,76).